Pankaine Spinal Heavy (Bupivacaine Hydrochloride, Anhydrous)

Bupivacaine hydrochloride, the active ingredient in Pankaine Spinal Heavy, is a local anesthetic presented as a sterile solution for intrathecal use. It provides prolonged sensory and motor block during surgical procedures and obstetric anesthesia. GNH USA supplies Pankaine Spinal Heavy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

GNH USA supplies Pankaine Spinal Heavy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Bupivacaine hydrochloride is employed in regional anesthesia to achieve profound nerve blockade for surgical and obstetric procedures.

- Cesarean section: provides long‑lasting analgesia for mother and newborn safety. - Orthopedic surgery: enables extended postoperative pain control after joint and limb operations. - Lower limb vascular surgery: offers sustained sensory block for procedures on the femoral or popliteal vessels. - Chronic pain management: used in epidural infusions for refractory cancer or neuropathic pain. - Urological ‑ procedures: facilitates pain‑free cystoscopy and transurethral resections. - Gynecologic surgery: supports analgesia during hysterectomy and laparoscopic procedures.

Bupivacaine may cause a range of adverse reactions, from mild to severe, depending on dose and administration site.

Common Side Effects: - Transient tingling or numbness at the injection site. - Mild hypotension due to sympathetic blockade. - Headache, often post‑dural puncture. - Nausea or vomiting. - Temporary urinary retention.

Serious or Rare Side Effects: - Cardiovascular toxicity, including arrhythmias or cardiac arrest. - Central nervous system toxicity such as seizures. - Persistent motor block lasting beyond the expected duration. - Allergic reactions ranging from rash to anaphylaxis. - Methemoglobinemia. - Spinal hematoma or infection at the injection site.

When using Bupivacaine for spinal anesthesia, clinicians should assess patient risk factors and monitor closely.

- Cardiac monitoring: observe for arrhythmias, especially in high‑dose cases. - Neurological assessment: check motor and sensory function regularly. - Dose limitation: adhere to recommended maximum doses to avoid systemic toxicity. - Contra‑indications: avoid in patients with known hypersensitivity to amide‑type local anesthetics. - Pregnancy: use only when benefit outweighs potential fetal risk. - Store at ambient temperature: keep in original container, protect from light and moisture.

Bupivacaine may interact with other agents that influence cardiac conduction or central nervous system activity.

Major Interactions (Avoid): - Class I anti‑arrhythmic drugs (e.g., quinidine, procainamide): increased risk of cardiotoxicity. - Beta‑blockers combined with high‑dose Bupivacaine: potentiates bradycardia and hypotension. - CNS depressants (e.g., benzodiazepines, opioids): may enhance neurotoxicity.

Moderate Interactions (Monitor Closely): - Calcium channel blockers: may augment hypotensive effects. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): potential for additive renal effects. - Magnesium sulfate: can increase neuromuscular blockade. - Lithium: heightened risk of neuro‑excitatory toxicity. - MAO inhibitors: may modify plasma levels of Bupivacaine.